Project Grant R43AI179388
- Life Pharms Inc. received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 19, 2025, through August 31, 2027. The award supports the development of LP10581, a novel antifungal therapeutic compound derived from the company's proprietary natural product collection. This small-molecular-weight compound (molecular weight 426) is designed to address the...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding to Clue Genetics Inc. for the development of a fungi-focused metabologenomics platform for natural product discovery. The key products and services to be delivered under this 1-year Phase I SBIR project include: Annotating biosynthetic gene clusters (BGCs) from 200 genomes selected from a diverse set of bioactive fungi to uncover new drugs,...
- Federal Project Grant Award Summary Shy Therapeutics, LLC received a $300,616 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with performance period September 1, 2025 through August 31, 2027. The award funds development of a novel class of antifungal small molecule therapeutics designed to combat drug-resistant fungal infections. The project delivers three primary research outputs: (1)...
- Federal Project Grant Award Summary Prokaryotics Incorporated received a $299,697 Project Grant awarded on September 19, 2025, from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel antifungal agent targeting FKS1 (fructose-1,6-bisphosphatase 1) and cell wall 1,3-D-glucan biosynthesis. The grant, with a completion date of August 31, 2026, supports research and development activities conducted at...
- Grant Award Summary Halomine Inc., doing business as Avantguard, received a $299,435 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded August 1, 2025, with completion scheduled for July 31, 2026. The grant supports the development and optimization of a novel, bio-inspired stabilized chloramine formulation designed to treat cutaneous fungal infections, particularly tinea (ringworm),...
- Federal Project Grant Award Summary Microbiotix, Inc. received a $299,946 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of novel benzyl-piperidine (BP) antifungal agents to treat intractable mucormycosis infections caused by the Mucorales fungal order, a World Health...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 in funding to Myconaut LLC to develop a scalable biological remediation method that uses synergistic interactions between fungi and plants to degrade and remove per- and polyfluoroalkyl substances (PFAS) from contaminated environments. The project aims to expand the understanding of fungal degradation of PFAS, evaluate the...
- The University of Minnesota's Office of Sponsored Projects Administration received a $125,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2027. This award supports fundamental basic research investigating the impacts of copy number variation on gene regulatory networks and fitness in Candida albicans, a common fungal pathogen. The...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pittsburgh a $437,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on azole resistance mechanisms in Candida parapsilosis causing bloodstream infections. The award, effective February 1, 2026 through January 31, 2028, supports research characterizing genetic and phenotypic diversity of C. parapsilosis populations...
- Federal Project Grant Award Summary Boston Children's Hospital received a $489,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, with a completion date of July 31, 2027. The award funds investigator-initiated biomedical research focused on identifying novel antifungal therapeutic targets in Candida albicans, a fungal pathogen responsible for invasive...
A PLATFORM TO IDENTIFY ANTIFUNGAL COMPOUNDS WITH NOVEL ACTION MECHANISMS - PROJECT SUMMARY THERE IS SOCIETAL NEED FOR NEW COMPOUNDS IN OUR ARSENAL OF DEFENSES AGAINST FUNGAL PATHOGENS, MANY OF WHICH ARE INCREASINGLY RESISTANT TO EXISTING THERAPEUTICS. ANTIFUNGAL COMPOUND DISCOVERY HAS BEEN FORGOTTEN OR NEGLECTED (SEE A REVIEW PUBLICATION 2021 AT RESEARCH STRATEGY). ONE OF THE BEST POSSIBLE SOURCES FOR NEW ANTIFUNGAL COMPOUNDS WITH POTENTIALLY NOVEL MECHANISMS OF ACTION IS WITHIN FILAMENTOUS FUNGI, WHICH HAVE THE GREATEST DIVERSITY OF MICROBIAL LIFE. THIS RESEARCH PROPOSAL ADVANCES THE SCIENCE OF METAGENOMICS, TO DEMONSTRATE ASPERGILLUS NIDULANS AS BOTH A HETEROLOGOUS HOST AND AN INITIAL ANTIFUNGAL SCREENING TARGET, TO INTEGRATE WITH RNA SEQUENCING AND FUNGAL PATHOGEN SCREENING OF FUNGAL BIOSYNTHETIC GENE CLUSTERS (BGCS) AND GENOMES, AND TO DISCOVER NOVEL ANTIFUNGAL CHEMICALS AND IDENTIFY THE BEST LEAD CANDIDATES FOR CLINICAL DEVELOPMENT. SCIENTISTS AT INTACT GENOMICS, AND UNIVERSITY OF WISCONSIN AT MADISON HAVE COMBINED FOUR KEY TECHNOLOGICAL BREAKTHROUGHS THAT RESULT IN AN IMPROVED PARADIGM FOR SCREENING SMALL MOLECULES. THE IMPROVEMENTS IN FUNGAL ARTIFICIAL CHROMOSOME (FAC) TOOLS INCLUDE: 1) AN IMPROVED METHODOLOGY FOR HETEROLOGOUS EXPRESSION OF FULL-LENGTH BGC-FACS; 2) THE FAC HETEROLOGOUS STRAINS EXPRESSING ANTIFUNGAL COMPOUNDS ALSO SHOWING ABNORMAL PHENOTYPES; 3) NEW ACTION MECHANISMS OF ABNORMAL PHENOTYPE BGC-FACS TO BE UNCOVERED BY RNA DEEP SEQUENCING; 4) A PANEL OF FUNGAL PATHOGENS FOR RAPID AND IMPROVED SCREENING METHOD TO IDENTIFY NOVEL ANTIFUNGAL COMPOUNDS. THIS PHASE I SBIR WILL BUILD UPON THE SUCCESS OF PREVIOUS RESEARCH BY SCREENING FACS FOR ANTIFUNGAL COMPOUNDS. WE WILL CHARACTERIZE THE ANTIFUNGAL AGENTS EXPRESSED BY BGC-FAC CLONES AND FAC LIBRARIES TO DETERMINE THE BEST LEAD CANDIDATES FOR CLINICAL DEVELOPMENT. LEAD CANDIDATES WILL HAVE NOVEL CHEMICAL STRUCTURES, HAVE HIGH POTENCY AGAINST MULTIPLE FUNGAL PATHOGENS, AND MINIMAL TOXICITY AGAINST HUMAN RED BLOOD CELL. EACH OF THE DIFFERENT TECHNOLOGIES NECESSARY FOR THE PROPOSED RESEARCH HAS BEEN PROVEN EFFECTIVE SEPARATELY; THEREFORE, THE SYNTHESIS OF THESE DIFFERENT METHODS HAS A HIGH PROBABILITY OF SUCCESS AND ALSO REPRESENTS A SIGNIFICANT ADVANCEMENT FOR THE SCIENCE OF ANTIFUNGAL DISCOVERY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 12/18/25 | ||
| Not listed | $300.2k | 7/19/23 |